Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
Not yet recruiting · NCT03645460 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA) | severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency | Not yet recruiting | Not applicable | 2026-08-26 | NCT03645460 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhen Geno-Immune Medical Institute | 43 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Shenzhen Geno-Immune Medical Institute | Shenzhen | China | 39 |